【レポートの概要（一部）】
1. Report Overview
1.1 Introduction to the Diabetes Industry and Market
1.2 Main Report Findings
1.3 This Study Provides the Following Knowledge
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Main Questions Answered by This Study
1.7 Who is This Study For?
1.8 Research Methods and Analysis
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Global Diabetes Drugs Market: Introduction
2.1 World Diabetes Drugs Market Segmentation
2.2 What is Diabetes?
2.3 How is Diabetes Classified?
2.4 Risk Factors, Disease Symptoms and Complications
2.5 Criteria for the Diagnosis of Diabetes
2.6 World and Regional Diabetes Incidence and Prevalence
2.7 The Economic Burden of Diabetes
2.8 Unmet Need
2.9 Leading Classes of Diabetic Medications
2.9.1 Type 1 Medication
2.9.1.1 Insulin
2.9.1.2 Surgical Options
2.9.2 Type 2 Medication
2.9.2.1 Alpha-glucosidase Inhibitors
2.9.2.2 Biguanides
2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2)
2.9.2.5 Thiazolidinediones
2.9.2.6 Sulfonylureas
2.9.2.7 Meglitinides
2.9.2.8 Other Injectable Medications
2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2016-2026
3.1 The World Diabetes Drug Market, 2015
3.1.1 Diabetes Treatment Market by Drug Class, 2015
3.1.2 Top Selling Diabetes Drugs, 2015
3.1.3 Generic Anti-Diabetes Drugs, 2015
3.2 World Diabetes Drugs Market: Revenue Forecast, 2016-2026
3.3 Injectable and Non-injectable Diabetes Drugs, 2016-2026
3.3.1 Injectable Diabetes Drugs Revenue Forecast, 2016-2026
3.3.2 Non-Injectable Diabetes Drugs Revenue Forecast, 2016-2026
4. Human Insulin and Analogues, 2016-2026
4.1 Insulin and Insulin Analogues Drugs, 2015
4.2 Insulin and Insulin Analogues: Revenue Forecast, 2016-2026
4.3 Insulin and Insulin Analogues: Market Trends, 2016-2026
4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance?
4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming?
4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2016-2026
4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2016-2026
4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2016-2026
4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2016-2026
4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2016-2026
4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2016-2026
5. Dipeptidyl Peptidase-4 Inhibitors (DPP-4) Market, 2016-2026
5.1 DPP-4 Market, 2015
5.2 DPP-4 Inhibitors Revenue Forecast, 2016-2026
5.3 Januvia (Sitagliptin; Merck (MSD)): Revenue Forecast, 2016-2026
5.4 Janumet (Sitagliptin and Metaformin; Merck & Co.): Revenue Forecast, 2016-2026
5.5 Galvus (Vildagliptin; Novartis): Revenue Forecast, 2016-2026
5.6 Onglyza (Saxagliptin; AstraZeneca): Revenue Forecast, 2016-2026
5.7 Nesina (Alogliptin; Takeda/Furiex Pharmaceuticals): Revenue Forecast, 2016-2026
5.8 Tradjenta (Linagliptin; Eli Lilly and Boehringer Ingelheim): Revenue Forecast, 2016-2026
6. Sulfonylureas Market, 2016-2026
6.1 Sulfonylureas Market, 2015
6.2 Sulfonylureas: Revenue Forecast 2016-2026
6.3 Sulfonylureas: Market Trends 2016-2026
6.3.1 New Opportunites for Sulfonylureas in Emerging Markets
6.3.2 Side Effects and Competitor Drugs Will Affect Sales
6.4 Diamicron (Gliclazide; Servier): Revenue Forecast, 2016-2026
6.5 Amaryl (Glimepiride; Sanofi): Revenue Forecast, 2016-2026
6.6 Glucotrol XL (Glipizide; Pfizer): Revenue Forecast, 2016-2026
7. Glucagon-Like Peptide-1 (GLP-1) Receptor agonists Market, 2016-2026
7.1 GLP-1 Receptor agonists Market, 2015
7.2 GLP-1 Receptor Agonists Revenue Forecast, 2016-2026
7.2.1 GLP-1 Receptor Agonists: Market Trends, 2016-2026
7.2.2 Promising New Approvals in the GLP-1 Class
7.2.3 GLP-1 Agonists and Weight Loss Results May Boost Revenues
7.3 Victoza (Liraglutide; Novo Nordisk): Revenue Forecast, 2016-2026
7.4 Byetta (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
7.5 Bydureon (Exenatide; AstraZeneca): Revenue Forecast, 2016-2026
8. Alpha-glucosidase Inhibitors Market, 2016-2026
8.1 Alpha-glucosidase Inhibitors Market, 2015
8.2 Alpha-glucosidase Inhibitors: Revenue Forecast, 2016-2026
8.2.1 Alpha-glucosidase Inhibitors: Market Trends, 2016-2026
8.2.1.1 Decline of Alpha-glucosidase Inhibitors Sales Due to Side Effects
8.2.1.2 Is a New Generation of Alpha-glucosidase Inhibitors Worthwhile?
8.3 Glucobay (Acarbose; Bayer AG): Revenue Forecast, 2016-2026
8.4 Basen (Voglibose; Takeda): Revenue Forecast, 2016-2026
8.5 Glyset (Miglitol; Pfizer): Revenue Forecast, 2016-2026
9. Meglitinides Market, 2016-2026
9.1 Meglitinides Market, 2015
9.2 Meglitinides: Revenue Forecast, 2016-2026
9.2.1 Meglitinides: Market Trends, 2016-2026
9.2.1.1 Combination Therapy: New Future for Meglitinides?
9.3 Prandin (Repaglinide; Novo Nordisk): Revenue Forecast, 2016-2026
9.4 Starlix (Nateglinide; Novartis): Revenue Forecast, 2016-2026
9.5 Glufast (Acarbose; Eisai): Revenue Forecast, 2016-2026
10. Thiazolidinediones Market, 2015
11. Sodium – glucose Co-transporter (SGLT2) Inhibitors Market, 2016-2026
11.1 SGLT2 Inhibitors Market, 2015
11.2 SGLT2 Revenue Forecast, 2016-2026
11.2.1 SGLT2 Market Trends, 2016-2026
11.3 Invokana (Canagliflozin; Johnson & Johnson): Revenue Forecast, 2016-2026
11.4 Forxiga (Dapagliflozin; AstraZeneca): Revenue Forecast, 2016-2026
11.5 Jardiance (Empagliflozin; Eli Lilly): Revenue Forecast, 2016-2026
12. Biguanides Market, 2016-2026
12.1 Biguanides Market, 2015
12.2 Biguanides: Revenue Forecast: 2016-2026
12.2.1 Biguanides: Market trends, 2016-2026
12.2.2 Metformin: Delay of Diabetes
12.2.3 Higher Mortality Associated with Combined Metformin and Insulin
12.3 Glucophage (Metformin; Merck (MSD)): Revenue Forecast, 2016-2026
12.4 Glumetza (Metformin Hydrochloride; Salix Pharmaceuticals): Revenue Forecast, 2016-2026
12.5 Fortamet (Metformin; Shionogi & Co): Revenue Forecast, 2016-2026
13. National Markets for Diabetes Drugs, 2016-2026
13.1 Leading National Markets for Diabetes Drugs, 2015
13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2016-2026
13.3 The US to Sustain its Market Leadership: Revenue Forecast 2016-2026
13.3.1 High Diabetes Prevalence within a Complex Healthcare System
13.4 The Japanese Market, Revenue Forecast, 2016-2026
13.4.1 Sanofi and Takeda Collaborate to Fight Diabetes in Japan
13.4.2 Novel Treatment Options in Japan
13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2015
13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market Revenue Forecasts, 2016-2026
13.5.2 Germany: Disease Treatment Measures Require Improvement – Revenue Forecast, 2016-2026
13.5.2.1 Tough Reimbursement Rules: More Data for Faster Approval?
13.5.3 French National Diabetes Market Revenue Forecast, 2016-2026
13.5.3.1 Great Standard of Care and Regulatory Reforms in France
13.5.4 The UK National Diabetes Market Revenue Forecast, 2016-2026
13.5.4.1 Faster Approvals for New Therapies in the UK
13.5.5 Italian National Diabetes Market Revenue Forecast, 2016-2026
13.5.6 Spanish National Diabetes Market Revenue Forecast, 2016-2026
13.6 China: The World’s Largest Diabetic Population – Revenue Forecast, 2016-2026
13.6.1 Presence of Multinational Companies and the Power of Buyers
13.6.2 Disparity in Regional Health Spending
13.6.3 Multi-Billion Dollar Investment to Improve Healthcare
13.7 The Indian Market: Revenue Forecast, 2016-2026
13.7.1 Focus on the Rural Population
13.8 The Russian National Diabetes Market, 2016-2026
13.8.1 High Out of Pocket Costs Reduce Compliance
13.9 Brazil: Improved Access to Care in Rural Areas – Revenue Forecast, 2016-2026
13.9.1 Localised Insulin Production in Brazil
13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2016
14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015-2016
14.1.1 Novo Nordisk
14.1.2 Eli Lilly & Boehringer Ingelheim
14.1.3 AstraZeneca
14.2 Human Insulins and Analogues: New Approvals
14.2.1 Insulin Glargine (Basaglar, Eli Lilly and Boehringer Ingelheim): Receives US Approval After Delays
14.2.2 Insulin Glargine (Toujeo, Sanofi): Will it Replace Lantus?
14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin Fails to Make an Impact
14.3 Human Insulins and Analogues: Pipeline Developments: New Approvals
14.3.1 Tresiba (Novo Nordisk): Opportunity Revival
14.3.2 MK-1293 (Merck (MSD) and Biogen Idec): Will Provide more Biosimilar Competition for Lantus
14.3.3 NN9924 (Novo Nordisk)
14.3.4 BIOD-123 (Biodel)
14.4 DPP-4 Inhibitors: Pipeline Developments
14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex Pharmaceuticals): Approved in Japan
14.4.2 Omarigliptin (MK-3102; Merck (MSD))
14.5 GLP-1: New Approvals and Pipeline, 2016
14.5.1 Trulicity (Dulaglutide; Eli Lilly): Potential for Blockbuster Status
14.5.2 Semaglutide (NN9535; Novo Nordisk)
14.5.3 Xultophy (IdegLira; Novo Nordisk)
14.5.4 ITCA 650 (Intarcia Theraputics)
14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2016
14.6.1 Sotagliflozin (Lexicon Pharmacuticals)
14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda)
14.6.3 MK8835 (Ertugliflozin; Merck (MSD))
14.6.4 Bexagliflozin (Theracos)
14.7 Other Diabetes Drugs: Pipeline Developments, 2016
14.7.1 DM199 (DiaMedica)
14.7.2 Glucokinase Activators
14.7.2.1 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2016-2026
15.1 SWOT Analysis of the Diabetes Drug Market, 2016-2026
15.2 Strengths
15.2.1 Promising Research and Development
15.2.2 Secondary Indications
15.2.3 Biological Drugs are Tougher to copy and Offer Variety
15.2.4 Market Competition
15.3 Weaknesses
15.3.1 Lack of Disease Awareness
15.3.2 Tougher Reimbursement Rules
15.3.3 Increased Risk of Cardiovascular Complications
15.3.4 Rising Cost of Drug Development
15.4 Opportunities
15.4.1 Rising Disease Prevalence
15.4.2 Emerging National Markets Hold Great Potential
15.4.3 Novel Insulin Delivery Methods
15.4.4 New Classes of Anti Diabetes Drugs
15.5 Threats
15.5.1 Type 1 Diabetes Vaccine
15.5.2 Increased Popularity of Other Therapies
15.5.3 Generic Drugs: Patent Expiries and Rising Competition
15.5.4 Regulatory Barriers – Challenges Getting Drug Approval
15.6 STEP Analysis of the World Diabetes Drugs Market, 2016-2026
15.6.1 Social Developments
15.6.2 Technological Advances
15.6.3 Economic Factors
15.6.4 Political Issues
16. Research Interviews
16.1 Interview with Professor Mark Baker, Clinical Practice Director of the National Institute of Healthcare Excellence (NICE)
17. Conclusions from the Research and Analysis
17.1 The Diabetes Market – Trends Shaping Those Treatments
17.2 Outlook of the Worlds Diabetes Drug Industry, 2016-2026
17.3 Insulin Will Continue to Dominate the Market
17.4 National Diabetes Market Outlooks, 2016-2026
17.5 Future Opportunities
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：糖尿病治療薬の世界市場2016-2026■ 英文：Diabetes World Drug Market Report 2016-2026
■ 発行日：2016年6月
■ 調査会社：visiongain
■ 商品コード：VGAIN60707
■ 調査対象地域：グローバル
- 自動車用ステアリングトルクセンサーの世界市場2018-2022About Automotive Steering Torque Sensor Automotive steering torque sensors are used in vehicles with electric power steering (EPS). These sensors measure the steering force applied by the driver and enable the sensitive control of electric steering support. The sensor is based on a contactless magnetic measuring principle and has a magnetic unit, sensor unit, and a flux tube unit. Technavio’s anal …
- 世界の生物活性材料及び製品（Bioactive Ingredients & Product）市場動向と予測（～2018）The market for bioactive ingredients is projected to experience a growth rate of 7.2% by 2018 to touch $33.6 billion. This estimation is attributed to the widening bioactive industry, which is a result of increased consumer awareness and health concerns. The Asia-Pacific region is the dominant market with increasing population, urbanization, and disposable income in countries such as India, China, …
- 3Dマシンビジョンの世界市場：PCベースマシンビジョン、スマートカメラベースマシンビジョン3D machine vision market is expected to be worth USD 1.63 Billion by 2020, growing at an estimated CAGR of 10.53% between 2015 and 2020. It holds a great potential across the automation industry. It is mainly used for the quality assurance and inspection applications to provide more accuracy in the manufacturing procedures and for proper inspection in detecting flaws. Healthcare accounted for the …
- 軍事シミュレーション・トレーニングの世界市場展望2017-2026According to Stratistics MRC, the Global Military Simulation and Training Market is accounted for $ 10.74 billion in 2017 and is expected to reach $ 17.57 billion by 2026 growing at a CAGR of 5.6%. Factors such as rising demand for adoption of virtual training for future generation, and reducing the budget of military equipment and training are driving the market growth. However, lack of lack of i …
- 自動車用アンチロールバーの世界市場：用途別、地域別Global Automotive Anti-roll Bar Market: About this market Technavio’s automotive anti-roll bar market analysis considers sales from both passenger cars and commercial vehicle applications. Our study also finds the sales of automotive anti-roll bar in APAC, Europe, MEA, North America, and South America. In 2019, the passenger car segment had a significant market share, and this trend is expected to …
- 化学療法誘発性骨髄抑制(Chemotherapy Induced Myelosuppression)：治療薬開発パイプライン動向（2015年上半期版）Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparati …
- 自動車用アダプティブ緊急ブレーキライトの世界市場2017-2021About Automotive Adaptive Emergency Brake LightsAdaptive brake lights alert drivers of the emergency brake being activated in the vehicle in front of them. The flashing of the brake lights indicates to the car behind that the emergency brakes are being activated. The brake lights are automatically activated to flash several times with different illuminating levels when the vehicle undergoes an eme …
- 泌尿生殖器薬の世界市場分析：指示薬別（前立腺、卵巣、膀胱、子宮頸がん、勃起不全、尿路感染症、尿失禁およびSTD）、製品別（泌尿器科学、ホルモン療法薬、婦人科、抗感染薬）、セグメント予測、2013 – 2024The genitourinary drugs market is expected to reach USD 29.7 billion by 2024, according to a new study by Grand View Research, Inc. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary dru …
- 世界の防弾服・個人防護市場動向2013-2023Why was the report written? “The Global Body Armor and Personal Protection Market 2013-2023” offers the reader detailed analysis of the global body armor and personal protection market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts. What are the key drivers behind recent market changes? The global body armor and persona …
- CLP Holdings Limited：発電所及びSWOT分析2013CLP Holdings Limited - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized an …
- レーザー切断機の世界市場：ファイバ、固体状態、ダイオード、その他Global Laser Cutting Machine Market: About this market Laser cutting machines have high-power lasers that can vaporize a range of materials, from steel to plastic with a high level of precision. Technavio’s laser cutting machines market analysis considers sales from fiber, solid-state, diode, and others. Our analysis also considers the sales of laser cutting machine in APAC, Europe, North America, …
- Statoil ASA：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Statoil ASA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Statoil ASA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operational …
- 狂犬病治療薬の世界市場About Rabies TreatmentRabies is a condition that causes thousands of deaths worldwide every year. Humans contract rabies when bitten by an animal infected with the rabies virus. The virus is transmitted when the saliva of the infected animal touches an open wound or mucous membrane. It infects the brain and ultimately leads to death. Technavio’s analysts forecast the global rabies treatment market …
- 世界のマウスモデル市場動向及び予測（～2018）：タイプ別（近交系、ノックアウト、条件付け）、技術別（マイクロインジェクション、胚性幹細胞）、疾患別（腫瘍学、免疫学、CNS）、サービス別（繁殖、冷凍保存、検疫）、ケア製品別（カゴ、寝床、餌）The global mice model market is segmented on the basis of type, technology, disease, and mice model services. By type, the market comprises of inbred, outbred, knockout, conditioned/surgically modified, hybrid/congenic, and spontaneous mutant mice. The market for mice model services is segmented into breeding, cryopreservation, quarantine, rederivation, genetic testing, model in-licensing, and oth …
- 軍用車両向け電子機器（ベトロニクス）の世界市場About Military Vetronics Vetronics (vehicle electronics) are used in military land vehicles for navigation, observation, and communication. They help in inter-vehicular or intra-vehicular communications. These systems increase warfare capabilities by enhancing the military’s capabilities with regard to intelligence, surveillance, and reconnaissance. Technavio's analysts forecast the global militar …
